TNFRSF18 and neoplasm: Retifanlimab is an inhibitor of programmed death ligand 1 (PD-L1), whereas INCAGN0187 is an inhibitor of glucocorticoid-induced TNFR-related protein (GITR), and the combination of both had been shown to improve anti-tumor immune response in preclinical models [34].